Tumor Oxygenation and Hypoxia Inducible Factor-1 Functional Inhibition via a Reactive Oxygen Species Responsive Nanoplatform for Enhancing Radiation Therapy and Abscopal Effects
Authors:
- Lingtong MengLMLingtong Meng
- Yali ChengYCYali Cheng
- Xiaoning TongXTXiaoning Tong
- Shaoju GanSGShaoju Gan
- Yawen DingYDYawen Ding
- Yu ZhangYZYu Zhang
- Chao WangCWChao Wang
- Jinhui WuJWJinhui Wu
- Yiqiao HuYHYiqiao Hu
- Ahu YuanAYAhu Yuan
Top Cited Papers
- 13 August 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 12 (8) , 8308-8322
Abstract
Hypoxia, and hypoxia inducible factor-1 (HIF-1), can induce tumor resistance to radiation therapy. To overcome hypoxia-induced radiation resistance, recent studies have described nanosystems to improve tumor oxygenation for immobilizing DNA damage and simultaneously initiate oxygen-dependent HIF-1α degradation. However, HIF-1α degradation is incomplete during tumor oxygenation treatment alone. Therefore, tumor oxygenation combined with residual HIF-1 functional inhibition is crucial to optimizing therapeutic outcomes of radiotherapy. Here, a reactive oxygen species (ROS) responsive nanoplatform is reported to successfully add up tumor oxygenation and HIF-1 functional inhibition. This ROS responsive nanoplatform, based on manganese dioxide (MnO2) nanoparticles, delivers the HIF-1 inhibitor acriflavine and other hydrophilic cationic drugs to tumor tissues. After reacting with overexpressed hydrogen peroxide (H2O2) within tumor tissues, Mn2+ and oxygen molecules are released for magnetic resonance imaging and tumor oxygenation, respectively. Cooperating with the HIF-1 functional inhibition, the expression of tumor invasion-related signaling molecules (VEGF, MMP-9) is obviously decreased to reduce the risk of metastasis. Furthermore, the nanoplatform could relieve T-cell exhaustion via downregulation of PD-L1, whose effects are similar to the checkpoint inhibitor PD-L1 antibody, and subsequently activates tumor-specific immune responses against abscopal tumors. These therapeutic benefits including increased X-ray-induced damage, downregulated resistance, and T-cell exhaustion related proteins expression achieved synergistically the optimal inhibition of tumor growth. Overall, this designed ROS responsive nanoplatform is of great potential in the sensitization of radiation for combating primary and metastatic tumors.Keywords
Funding Information
- Ministry of Science and Technology of the People's Republic of China (2017YFA0205400)
- Ministry of Education of the People's Republic of China
- National Natural Science Foundation of China (81603043, 81473146)
- State Key Laboratory of Natural Medicines, China Pharmaceutical University (SKLNMKF201608)
This publication has 45 references indexed in Scilit:
- Perfluorooctyl bromide & indocyanine green co-loaded nanoliposomes for enhanced multimodal imaging-guided phototherapyBiomaterials, 2018
- Drug-induced co-assembly of albumin/catalase as smart nano-theranostics for deep intra-tumoral penetration, hypoxia relieve, and synergistic combination therapyJournal of Controlled Release, 2017
- Albumin‐Templated Manganese Dioxide Nanoparticles for Enhanced Radioisotope TherapySmall, 2017
- Ultrasound-mediated destruction of oxygen and paclitaxel loaded lipid microbubbles for combination therapy in hypoxic ovarian cancer cellsUltrasonics Sonochemistry, 2016
- The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrenceNature Reviews Cancer, 2015
- Multifunctional Albumin–MnO2 Nanoparticles Modulate Solid Tumor Microenvironment by Attenuating Hypoxia, Acidosis, Vascular Endothelial Growth Factor and Enhance Radiation ResponseACS Nano, 2014
- Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vesselsNature Communications, 2012
- Strategies to improve radiotherapy with targeted drugsNature Reviews Cancer, 2011
- Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy responseNature Reviews Cancer, 2008
- The role of radiotherapy in cancer treatmentCancer, 2005